Follow us on:

Sativa Group take an important step forward with controlled drug licence

Sativa Group (NEX: SATI) CEO Henry Lees-Buckley joins DirectorsTalk to discuss the award of a Controlled Drug Licence from the UK Home Office. Henry explains why this is an important step forward for the company, what the licence enables the Sativa to do, what it means for the company and why this is such an important achievement.

Sativa Group PLC joined the NEX Exchange on 29th March 2018 as the first UK listed medicinal cannabis investment vehicle. Since then, the Company has changed its business strategy to capitalise on changes in the UK and European laws and regulations surrounding the cannabis industry.

Find more news, interviews, share price & company profile here for:Goodbody Health

Share this interview

Other Interviews

INTERVIEW: Sativa Investments Enlist Retail Expert Chris Jones January 16, 2019
INTERVIEW: Why Sativa Investments are moving from Investment to operating company January 8, 2019
INTERVIEW: Sativa Investments Some big changes since IPO September 28, 2018
INTERVIEW: Sativa Investments UK interest in medicinal cannabis is building June 26, 2018
INTERVIEW: Why Sativa Investments Plc is to change its investment policy June 7, 2018

More News

Sativa Group records a record month of revenues July 10, 2020
Sativa Group working on its Novel Food application in partnership with Stillcanna June 26, 2020
Sativa Group implement new management incentive plan June 4, 2020
Sativa Group Revenue increased from £0.26m to £1.45 million in the year to 31 December 2019 June 4, 2020
Sativa Group due diligence of StillCanna Inc. May 20, 2020
Sativa Group enters into a LOI with StillCanna, Inc April 22, 2020
Sativa Group launch of cannabinoid cannabigerol (CBG) hand cleanser March 18, 2020
Sativa Group comment on faster access for patients to cannabis-based medicinal products March 3, 2020
Sativa Group Goodbody Botanicals secures significant product listing with WH Smith Travel February 20, 2020
Sativa Group welcomes Food Standard Authority guidelines February 14, 2020

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.